Form 4 Acumen Pharmaceuticals Inc For: 17 June
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Acumen Pharmaceuticals Inc (ABOS)
Acumen Pharmaceuticals Inc stock price live, this page displays NASDAQ ABOS stock exchange data. View the ABOS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Acumen Pharmaceuticals Inc real time stock price chart below.
What Is the Acumen Pharmaceuticals Inc Stock Price Today?
The Acumen Pharmaceuticals Inc stock price today is 2.615.
What Is the Stock Symbol for Acumen Pharmaceuticals Inc?
The stock symbol for Acumen Pharmaceuticals Inc is "ABOS."
What Stock Exchange Does Acumen Pharmaceuticals Inc Trade On?
Acumen Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Acumen Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Acumen Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABOS quote. (ISIN: US00509G2093)
What Is the Acumen Pharmaceuticals Inc Stock Price Today?
The Acumen Pharmaceuticals Inc stock price today is 2.615.
What Is the Stock Symbol for Acumen Pharmaceuticals Inc?
The stock symbol for Acumen Pharmaceuticals Inc is "ABOS."
What Stock Exchange Does Acumen Pharmaceuticals Inc Trade On?
Acumen Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Acumen Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Acumen Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABOS quote. (ISIN: US00509G2093)
2.615
-0.085(-3.15%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.540
2.720
52 wk Range
1.190
3.600
ABOS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.5402.720
52 wk Range
1.1903.600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABOS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
7.400
Upside
+182.98%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 144 ACUMEN PHARMACEUTICALS For: 15 June
- Investing.com
- Form 144 ACUMEN PHARMACEUTICALS For: 16 June
- Investing.com
- Form 4 Acumen Pharmaceuticals Inc For: 17 June
- Investing.com
- Form 144 ACUMEN PHARMACEUTICALS For: 16 June
- Investing.com
- Form 8K Acumen Pharmaceuticals Inc For: 16 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.400
(+182.98% Upside)
Acumen Pharmaceuticals Inc Earnings Call Summary for Q1/2026
- Acumen reported Q1 2026 EPS of -$0.33, beating forecast of -$0.37 by 10.81%; stock fell 3.11% despite beat to $2.49 in premarket trading.
- Company maintains $128.4M cash position extending runway into early 2027; Q1 net loss of $20.7M with reduced R&D ($16.5M) and G&A ($4.7M) expenses.
- Successfully completed enrollment for ALTITUDE-ad Phase II trial; top-line results expected late 2026 with potential market impact for Alzheimer's therapy.
- Plans to license two compounds from JCR Pharma in Q2 2026; IND filing for Enhanced Brain Delivery program anticipated by mid-2027.
- Market skepticism persists around Alzheimer's therapies despite infrastructure improvements; stock delivered 137% return over past year amid volatility.
Last Updated: 05/15/2026, 09:20 PM
Read Full TranscriptEarnings
Latest Release
May 12, 2026
EPS / Forecast
-0.33 / -0.37
Revenue / Forecast
-- / --
Compare ABOS to Peers and Sector
Metrics to compare | ABOS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABOSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −3.1x | −0.4x | |
PEG Ratio | −0.41 | −0.05 | 0.00 | |
Price/Book | 2.1x | 2.6x | 2.6x | |
Price / LTM Sales | - | 91.1x | 3.0x | |
Upside (Analyst Target) | 196.3% | 225.1% | 51.9% | |
Fair Value Upside | Unlock | −4.7% | 9.1% | Unlock |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer’s disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Acumen Pharmaceuticals (ABOS) Stock Price Today?
The Acumen Pharmaceuticals stock price today is 2.615 USD.
What Stock Exchange Does Acumen Pharmaceuticals Trade On?
Acumen Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Acumen Pharmaceuticals?
The stock symbol for Acumen Pharmaceuticals is "ABOS."
What Is the Acumen Pharmaceuticals Market Cap?
As of today, Acumen Pharmaceuticals market cap is 189.240M USD.
What Is Acumen Pharmaceuticals's Earnings Per Share (TTM)?
The Acumen Pharmaceuticals EPS (TTM) is -1.850.
When Is the Next Acumen Pharmaceuticals Earnings Date?
Acumen Pharmaceuticals will release its next earnings report on Aug 17, 2026.
From a Technical Analysis Perspective, Is ABOS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Acumen Pharmaceuticals Stock Split?
Acumen Pharmaceuticals has split 0 times.
How Many Employees Does Acumen Pharmaceuticals Have?
Acumen Pharmaceuticals has 61 employees.
What is the current trading status of Acumen Pharmaceuticals (ABOS)?
As of Jul 10, 2026, Acumen Pharmaceuticals (ABOS) is trading at a price of 2.615 USD, with a previous close of 2.700 USD. The stock has fluctuated within a day range of 2.540 USD to 2.720 USD, while its 52-week range spans from 1.190 USD to 3.600 USD.
What Is Acumen Pharmaceuticals (ABOS) Price Target According to Analysts?
The average 12-month price target for Acumen Pharmaceuticals is 7.400 USD, with a high estimate of 10 USD and a low estimate of 4 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +182.98% Upside potential.
What Is the ABOS Premarket Price?
ABOS's last pre-market stock price is 2.680 USD. The pre-market share volume is 637.000, and the stock has decreased by -0.020, or -0.740%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.